Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 558 clinical trials
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to

  • 0 views
  • 25 Jan, 2021
  • 1 location
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per

atezolizumab
carcinoma
measurable disease
nivolumab
pd-l1
  • 13 views
  • 23 Jan, 2021
  • 1 location
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer

In this trial chemotherapy regimen FOLFOX with intrahepatic administration of oxaliplatin is combined with immunotherapy (nivolumab and ipilimumab) for the group of patients with multiple liver

oxaliplatin
measurable disease
folfox regimen
nivolumab
metastasis
  • 0 views
  • 26 Jan, 2021
  • 1 location
  • 0 views
  • 02 Feb, 2021
  • 2 locations
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

diagnosed with advanced (stage IV) NSCLC, irrespective of PD-L1 status, and who have oligoprogressed to both immunotherapy with an anti PD-1 agent (e.g., pembrolizumab or nivolumab) and 1 line of

  • 0 views
  • 01 Mar, 2021
  • 1 location
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks) concurrently with radiation (6Gy x 5 fractions). Nivolumab (every 2 weeks) will be given in addition to ipilimumab on day

  • 3 views
  • 25 Jan, 2021
  • 3 locations
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Natural Killer (NK) cells, combined with standard of care (SOC) adjuvant chemotherapy, followed by nivolumab, an antibody against Programmed Cell Death 1 (PD-1), to maintain and boost the vaccine's effect

  • 0 views
  • 26 Jan, 2021
  • 1 location
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

therapy with either nivolumab or pembrolizumab. In order to account for the variability of response kinetics to PD-1 directed therapy, patients will be enrolled in 3 parallel cohorts based on the

  • 22 views
  • 26 Jan, 2021
  • 2 locations
Autologous Dendritic Cells Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG

responses. Therapeutic DC vaccines are followed by four cycles of Nivo/Ipi double checkpoint blockade and a Nivolumab monotherapy maintenance in order to optimize the induced T-cell response.

  • 0 views
  • 26 Jan, 2021
  • 3 locations
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like

head and neck cancer
head and neck carcinoma
cancer
nivolumab
cavities
  • 100 views
  • 05 Feb, 2021
  • 14 locations